Search Results - "Boehnke Michaud, Laura"

Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience by GUARNERI, Valentina, LENIHAN, Daniel J, VALERO, Vicente, DURAND, Jean-Bernard, BROGLIO, Kristine, HESS, Kenneth R, BOEHNKE MICHAUD, Laura, GONZALEZ-ANGULO, Ana M, HORTOBAGYI, Gabriel N, ESTEVA, Francisco J

“…To evaluate the cardiac safety of long-term trastuzumab therapy in patients with human epidermal growth receptor 2 (HER2) -overexpressing metastatic breast…”
Get full text

Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition by Conley, Robert B, Adib, Gemma, Adler, Robert A, Åkesson, Kristina E, Alexander, Ivy M, Amenta, Kelly C, Blank, Robert D, Brox, William Timothy, Carmody, Emily E, Chapman‐Novakofski, Karen, Clarke, Bart L, Cody, Kathleen M, Cooper, Cyrus, Crandall, Carolyn J, Dirschl, Douglas R, Eagen, Thomas J, Elderkin, Ann L, Fujita, Masaki, Greenspan, Susan L, Halbout, Philippe, Hochberg, Marc C, Javaid, Muhammad, Jeray, Kyle J, Kearns, Ann E, King, Toby, Koinis, Thomas F, Koontz, Jennifer Scott, Kužma, Martin, Lindsey, Carleen, Lorentzon, Mattias, Lyritis, George P, Michaud, Laura Boehnke, Miciano, Armando, Morin, Suzanne N, Mujahid, Nadia, Napoli, Nicola, Olenginski, Thomas P, Puzas, J Edward, Rizou, Stavroula, Rosen, Clifford J, Saag, Kenneth, Thompson, Elizabeth, Tosi, Laura L, Tracer, Howard, Khosla, Sundeep, Kiel, Douglas P

“…ABSTRACT Osteoporosis‐related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among…”
Get full text

Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer by Michaud, Laura Boehnke

“…To discuss trends in breast and prostate cancer prevalence and survival; risk factors for bone loss, osteoporosis, and fractures and the approach to risk…”
Get full text

The Epothilones: How Pharmacology Relates to Clinical Utility by Michaud, Laura Boehnke

“…Objective: To review the pharmacologic properties of a novel class of chemotherapeutic agents, the epothilones, and to summarize findings from recent clinical…”
Get full text

Treatment-experienced breast cancer by Michaud, Laura Boehnke

“…Breast cancer, the second leading cause of cancer mortality among women in the U.S., following lung cancer is described and the number of treatment options for…”
Get full text

Combination Endocrine Therapy in the Management of Breast Cancer by Boehnke Michaud, Laura, Jones, Kellie L., Buzdar, Aman U.

“…Combination endocrine therapy has long been sought after as a means to better treat breast cancer. Agents that suppress estrogen production are given with…”
Get full text

Cancer-treatment-induced bone loss, part 1 by Michaud, Laura Boehnke, Goodin, Susan

“…The pathophysiology, frequency, sequelae, diagnosis, and treatment of cancer-treatment-induced bone loss (CTIBL) are discussed. CTIBL is a long-term…”
Get full text

Oncology pharmacists in health care delivery: vital members of the cancer care team by Holle, Lisa Marie, Boehnke Michaud, Laura

“…The goal of this summary is to outline the unique knowledge, skills, and functions provided by oncology pharmacists to facilitate the provision of…”
Get full text

The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer by Boehnke Michaud, Laura

“…Background. The epothilones are a new class of microtubule-stabilizing drugs that exert potent antitumor activity against taxane-resistant and multidrug…”
Get full text

Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond by Esteva, Francisco J., Valero, Vicente, Pusztai, Lajos, Boehnke‐Michaud, Laura, Buzdar, Aman U., Hortobagyi, Gabriel N.

“…Chemotherapy plays an important role in the management of metastatic breast cancer. The anthracyclines (doxorubicin, epirubicin) and the taxanes (paclitaxel,…”
Get full text

Cancer-treatment-induced bone loss, part 2 by Michaud, Laura Boehnke, Goodin, Susan

“…The pathophysiology, frequency, sequelae, diagnosis, and treatment of cancer-treatment-induced bone loss (CTIBL) are discussed. CTIBL is a long-term…”
Get full text

Risks and benefits of taxanes in breast and ovarian cancer by MICHAUD, Laura Boehnke, VALERO, Vicente, HORTOBAGYI, Gabriel

“…The taxanes are a unique class of agents with a broad spectrum of clinical activity. They act by binding to tubulin, producing unnaturally stable microtubules…”
Get full text

Dietary supplements in patients with cancer: Risks and key concepts, part 1 by Michaud, Laura Boehnke, Karpinski, Julie Phillips, Jones, Kellie L, Espirito, Janet

“…The risks and key concepts regarding the use of dietary supplements in patients with cancer are described. There are six common characteristics of dietary…”
Get full text

Dietary supplements in patients with cancer: Risks and key concepts, part 2 by Michaud, Laura Boehnke, Karpinski, Julie Phillips, Jones, Kellie L, Espirito, Janet

“…The risks and key concepts regarding the use of dietary supplements in patients with cancer are described. There are six common characteristics of dietary…”
Get full text

Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition by Conley, Robert B, Adib, Gemma, Adler, Robert A, Åkesson, Kristina E, Alexander, Ivy M, Amenta, Kelly C, Blank, Robert D, Brox, William Timothy, Carmody, Emily E, Chapman-Novakofski, Karen, Clarke, Bart L, Cody, Kathleen M, Cooper, Cyrus, Crandall, Carolyn J, Dirschl, Douglas R, Eagen, Thomas J, Elderkin, Ann L, Fujita, Masaki, Greenspan, Susan L, Halbout, Philippe, Hochberg, Marc C, Javaid, Muhammad, Jeray, Kyle J, Kearns, Ann E, King, Toby, Koinis, Thomas F, Koontz, Jennifer Scott, Kužma, Martin, Lindsey, Carleen, Lorentzon, Mattias, Lyritis, George P, Michaud, Laura Boehnke, Miciano, Armando, Morin, Suzanne N, Mujahid, Nadia, Napoli, Nicola, Olenginski, Thomas P, Puzas, J Edward, Rizou, Stavroula, Rosen, Clifford J, Saag, Kenneth, Thompson, Elizabeth, Tosi, Laura L, Tracer, Howard, Khosla, Sundeep, Kiel, Douglas P

“…Osteoporosis-related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among treatment…”
Get full text

Antiemesis by Ettinger, David S, Armstrong, Debra K, Barbour, Sally, Berger, Michael J, Bierman, Philip J, Bradbury, Bob, Ellis, Georgianna, Kirkegaard, Steve, Kloth, Dwight D, Kris, Mark G, Lim, Dean, Michaud, Laura Boehnke, Nabati, Lida, Noonan, Kim, Rugo, Hope S, Siler, Darby, Sorscher, Steven M, Stelts, Sundae, Stucky-Marshall, Lisa, Todaro, Barbara, Urba, Susan G

Get more information

Secondary Fracture Prevention: Consensus Clinical Recommendations From a Multistakeholder Coalition by Conley, Robert B., Adib, Gemma, Adler, Robert A., Åkesson, Kristina E., Alexander, Ivy M., Amenta, Kelly C., Blank, Robert D., Brox, William Timothy, Carmody, Emily E., Chapman-Novakofski, Karen, Clarke, Bart L., Cody, Kathleen M., Cooper, Cyrus, Crandall, Carolyn J., Dirschl, Douglas R., Eagen, Thomas J., Elderkin, Ann L., Fujita, Masaki, Greenspan, Susan L., Halbout, Philippe, Hochberg, Marc C., Javaid, Muhammad, Jeray, Kyle J., Kearns, Ann E., King, Toby, Koinis, Thomas F., Koontz, Jennifer Scott, Kužma, Martin, Lindsey, Carleen, Lorentzon, Mattias, Lyritis, George P., Michaud, Laura Boehnke, Miciano, Armando, Morin, Suzanne N., Mujahid, Nadia, Napoli, Nicola, Olenginski, Thomas P., Puzas, J. Edward, Rizou, Stavroula, Rosen, Clifford J., Saag, Kenneth, Thompson, Elizabeth, Tosi, Laura L., Tracer, Howard, Khosla, Sundeep, Kiel, Douglas P.

“…Osteoporosis-related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among treatment…”
Get full text

NCCN Guidelines Insights: Antiemesis, Version 2.2017 by Berger, Michael J, Ettinger, David S, Aston, Jonathan, Barbour, Sally, Bergsbaken, Jason, Bierman, Philip J, Brandt, Debra, Dolan, Dawn E, Ellis, Georgiana, Kim, Eun Jeong, Kirkegaard, Steve, Kloth, Dwight D, Lagman, Ruth, Lim, Dean, Loprinzi, Charles, Ma, Cynthia X, Maurer, Victoria, Michaud, Laura Boehnke, Nabell, Lisle M, Noonan, Kim, Roeland, Eric, Rugo, Hope S, Schwartzberg, Lee S, Scullion, Bridget, Timoney, John, Todaro, Barbara, Urba, Susan G, Shead, Dorothy A, Hughes, Miranda

“…The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management for chemotherapy-induced nausea and…”
Get more information

Myeloid growth factors by Crawford, Jeffrey, Armitage, James, Balducci, Lodovico, Bennett, Charles, Blayney, Douglas W, Cataland, Spero R, Dale, David C, Demetri, George D, Erba, Harry P, Foran, James, Freifeld, Alison G, Goemann, Marti, Heaney, Mark L, Htoy, Sally, Hudock, Susan, Kloth, Dwight D, Kuter, David J, Lyman, Gary H, Michaud, Laura Boehnke, Miyata, Sarah C, Tallman, Martin S, Vadhan-Raj, Saroj, Westervelt, Peter, Wong, Michael K

Get more information

Myeloid growth factors. Clinical practice guidelines in oncology by Crawford, Jeffrey, Althaus, Betsy, Armitage, James, Balducci, Lodovico, Bennett, Charles, Blayney, Douglas W, Cataland, Spero R, Dale, David C, Demetri, George D, Erba, Harry P, Foran, James, Freifeld, Alison G, Heaney, Mark L, Htoy, Sally, Kloth, Dwight D, Lyman, Gary H, Messersmith, Wells A, Michaud, Laura Boehnke, Miyata, Sarah C, Robbins, Amy, Tallman, Martin S, Vadhan-Raj, Saroj, Westervelt, Peter, Wong, Michael K

Get more information